27 January 2016 - AbbVie announced today that the U.S. FDA granted breakthrough therapy designation for the investigational agent venetoclax in combination with hypomethylating agents for the treatment of patients with untreated (treatment-naïve) acute myeloid leukaemia who are ineligible to receive standard induction therapy (high-dose chemotherapy).

For more details, go to: http://abbvie.mediaroom.com/2016-01-27-Venetoclax-Receives-3rd-Breakthrough-Therapy-Designation-from-the-FDA-for-the-Combination-Treatment-of-Patients-with-Untreated-Acute-Myeloid-Leukemia-not-Eligible-for-Standard-Induction-Chemotherapy